Published

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Unknown
Date: 2023-07-18
Source: Europe PMC
DOI: Unavailable
PubMed: Unavailable

Authors

Goodwin G Marwood L Mistry S Nowakowska A Simmons H Tsai J Williams S Young M Malievskaia E.

Watch author

Topics and keywords

psilocybin Depression Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.New England Journal of Medicine · 2022-10-31 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-12 Psilocybin shows promising results in subjects continuing to use an antidepressantThe Brown University Psychopharmacology Update · 2023-10-03 Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-29 The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2021-12-31 The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trialNeuroscience Applied · 2021-12-31